CSL Behring Competitors and Similar CompaniesClear all

CSL Behring's competitors and similar companies include Biotest, Abeona Therapeutics, Octapharma and Grifols.

	CSL Behring CSL Behring is a provider of life-saving medicines.	Biotest Biotest is a company that specializes in the fields of clinical immunology, haematology as well as intensive care and emergency medicine.	Abeona Therapeutics Abeona Therapeutics is focusing on developing innovative therapies, including gene therapies, for rare diseases, including Sanfilippo Syndrome.	Octapharma Octapharma is one of the largest human protein manufacturers, developing and producing human proteins from human plasma and human cell lines.	Grifols Grifols is a pharmaceutical and chemical manufacturer.
Founding Date	Founding Date 1904	Founding Date 1946	Founding Date 2013	Founding Date 1983	Founding Date 1909
Type	Type Subsidiary	Type Public	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare clinical research drug development emergency	Tags Healthcare clinics genetics therapy	Tags Manufacturing & Industrial drug development pharma	Tags Healthcare clinics healthtech hospitals pharma therapy
Locations	Locations King of Prussia, US HQ Broadmeadows, AU Parkville, AU Parkville, AU Wien, AT Mechelen, BE see more	Locations Dreieich, DE HQ	Locations Dallas, US HQ Madrid, ES Cleveland, US New York, US	Locations Lachen, CH HQ Pyrmont, AU Wien, AT Baku, AZ Minsk, BY Anderlecht, BE see more	Locations Sant Cugat del Vallès, ES HQ Buenos Aires, AR Clayton South, AU São Paulo, BR Mississauga, CA Las Condes, CL see more
Employees	Employees 7,5692% decrease	Employees 2,4265% increase	Employees 5737% decrease	Employees 12,000	Employees 23,800
Valuation ($)	Valuation ($) N/A	Valuation ($) 1.5 b	Valuation ($) 284.6 m	Valuation ($) N/A	Valuation ($) 6.7 b
Financial
Revenue (est.)	Revenue (est.) $7.9b (FY, 2020)	Revenue (est.) €648.9m (FY, 2025)	Revenue (est.) $5.8m (FY, 2025)	Revenue (est.) €2.5b (FY, 2021)	Revenue (est.) €7.5b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods €540.5m (FY, 2025)	Cost of goods $1.5m (FY, 2025)	Cost of goods €1.7b (FY, 2021)	Cost of goods €4.2b (FY, 2025)
Gross profit	Gross profit $4.5b (FY, 2020)	Gross profit €142.7m (FY, 2025)	Gross profit $4.3m (FY, 2025)	Gross profit €808.2m (FY, 2021)	Gross profit €3.3b (FY, 2025)
Net income	Net income N/A	Net income (€70.7m) (FY, 2025)	Net income $71.2m (FY, 2025)	Net income €438.3m (FY, 2021)	Net income €500m (FY, 2025)
Operating ⚠
Countries	Countries 100 (Dec, 2020)	Countries N/A	Countries N/A	Countries N/A	Countries 110 (H2, 2021)
Plasma Collection Centers	Plasma Collection Centers 275 (Sep, 2020)	Plasma Collection Centers N/A	Plasma Collection Centers N/A	Plasma Collection Centers N/A	Plasma Collection Centers 366 (FY, 2021)